Examples of differentially methylated regions in prostate cancer, including the recurrent DMR at the HES5 gene promoter (adapted from Massie et al. ERC 2015)
References
Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R; UK Prostate ICGC Group, Warren AY, Tavaré S, Neal DE, Lynch AG. HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocr Relat Cancer. 2015 Apr;22(2):131-44. doi: 10.1530/ERC-14-0454. Epub 2015 Jan 5. PMID: 25560400; PMCID: PMC4335379. https://doi.org/10.1530%2FERC-14-0454
Paziewska A, Dabrowska M, Goryca K, Antoniewicz A, Dobruch J, Mikula M, Jarosz D, Zapala L, Borowka A, Ostrowski J. DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy. British Journal of Cancer. 2014 Aug;111(4):781-9. https://doi.org/10.1038/bjc.2014.337
Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proceedings of the National Academy of Sciences. 1994 Nov 22;91(24):11733-7. https://doi.org/10.1073/pnas.91.24.11733
Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. European Urology. 2004 Dec 1;46(6):698-708. https://doi.org/10.1016/j.eururo.2004.07.022
